Skip to main content

Table 3 Cox regression for time to first occurrence of DAIDS Grade 3 or 4 ALT and/or AST abnormalities in TPV/r-based and comparator PI/r- (CPI/r-) based cART RESIST patients

From: Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Parameter

HR1 (p-value)

95% Confidence Interval

Treatment group:

2.77 (<0.0001)

1.71, 4.48

   TPV/r v CPI/r

  

HBV or HCV co-infection:

2.00 (0.0057)

1.22, 3.27

   yes vs. no

  

ALT/AST at baseline:

2.05 (0.0709)

0.94, 4.48

   Grade ≥2 vs. ≤Grade 1

  

CD4+ cells at baseline:

1.46 (0.0643)

0.98, 2.18

   >200 vs. ≤200 cells/mm3

  
  1. 1 Hazard Ratio
  2. Model further controlled for sex, race and concurrent use of T-20 (none were statistically significant).